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Protein-Templated Dynamic Combinatorial Chemistry: Brief
Overview and Experimental Protocol
Alwin M. Hartman,[a,b,c][‡] Robin M. Gierse,[a,b,c][‡] and Anna K. H. Hirsch*[a,b,c]
Abstract: Dynamic combinatorial chemistry (DCC) is a power-
ful tool to identify bioactive compounds. This efficient tech-
nique allows the target to select its own binders and circum-
vents the need for synthesis and biochemical evaluation of all
individual derivatives. An ever-increasing number of publica-
Introduction
Since its dawn more than two decades ago, combinatorial
chemistry approaches[1–5] have developed into target-directed
dynamic combinatorial chemistry (tdDCC) and have matured as
a hit-identification tool.[6–11] A growing number of groups have
shown the general applicability and scope of tdDCC for the
identification of modulators of targets.[6,12–20] tdDCC refers to
general pharmacologically relevant targets which next to pro-
Figure 1. Schematic representation of target-directed dynamic combinatorial chemistry.
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tions report the use of DCC on biologically relevant target pro-
teins. This minireview complements previous reviews by focus-
ing on the experimental protocol and giving detailed examples
of essential steps and factors that need to be considered, such
as protein stability, buffer composition and cosolvents.
teins also include DNA and RNA, whereas protein-templated
DCC (ptDCC) only refers to proteins. Several reviews and book
chapters on tdDCC have been published in recent years.[21–23]
This minireview covers our work on ptDCC and provides the
key features of our protocol, explaining the essential steps in
designing a successful ptDCC experiment.
Carefully chosen building blocks are connected in a reversi-
ble manner via covalent or noncovalent bonds to form a dy-
namic combinatorial library (DCL) (Figure 1). Biocompatibility,
pH dependence, temperature, solubility and stability of the
components are important factors, which should be taken into
account. The ideal DCLs do not require cosolvents, however, it
can occur that the formed products have a lower solubility than
the building blocks and in order to keep all compounds in solu-
tion, a cosolvent such as dimethyl sulfoxide (DMSO) is com-
monly used. Precipitation of DCL components could lead to an
undesired shift in the equilibrium. By contrast, a desired shift of
the equilibrium can be obtained by the addition of an external
stimulus, such as a protein target. There are in general two
different approaches that can be followed in ptDCC: “adaptive
DCC”, in which the target is present during the formation of
the DCL and “pre-equilibrated DCC”, in which the target is
added after the DCL is established. An advantage of pre-equili-
brated DCC is that the exchange chemistry can be applied in
Minireview
conditions which are not tolerated by the protein. A disadvan-
tage is that the screening step is performed under static condi-
tions and no amplification effects can be observed since the
protein does not alter the equilibrium.
In ptDCC, the member(s) of DCLs, which bind best will be
amplified, leading to an increase in their concentration com-
Figure 2. DCC approaches: comparative and non-comparative. In the compar-
ative approach the library in presence of a target is compared to the library
in absence of the target. In the non-comparative approaches, the hit–target
complexes will be separated from the mixture and analyzed as a complex or
as released hits. Adapted from Frei et al.[21]
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pared to a control reaction without the external stimulus. These
binders can then be further evaluated for their biochemical
properties.
To enable a comparative analysis of DCLs, a blank reaction,
without the target, should be run concurrent with a templated
reaction. Another approach of DCC is non-comparative, in
which the hits can be analyzed in complex with the target or
after being released from the target. There are different tech-
niques that can be used to analyze the DCLs: liquid and size-
exclusion chromatography coupled to mass spectrometry, NMR
spectroscopy, fluorescence spectroscopy and X-ray crystallogra-
phy. Figure 2 illustrates the comparative approach vs. the non-
comparative approach, which can be adopted in DCC. The reac-
tion mixture can be “frozen”, in order to prevent the library
from re-equilibrating during the analysis. In the case of acyl-
hydrazone chemistry, this can be achieved by an increase in
pH. Denaturation by heat, addition of a solvent or (ultra-fast)
centrifugation ensures that all binders are released from the
protein before analysis.
1. Reversible Reaction Suitable for DCC
Only a limited number of reversible reactions have been used
thus far, they are summarized in Scheme 1. One of the most
frequently used reactions is the (acyl-)hydrazone formation,
which combines ketone or aldehyde building blocks with
(acyl-)hydrazides. This condensation reaction can take place in
water, making it biocompatible.[24] The synthesis of the building
blocks is generally straightforward or they may be commercially
available.
At physiological conditions, neutral pH and room tempera-
ture, acylhydrazone formation and exchange are relatively slow.
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Scheme 1. Reversible reactions used in target-directed DCC to identify bioactive compounds. Adapted from Van der Vlag and Hirsch.[23]
At acidic pH, the equilibrium is reached rapidly. However,
Greaney and co-workers have shown that the pH dependence
can be influenced by the addition of a nucleophilic catalyst.
Table 1. Protein-templated DCC studies reported over the past five years, in which a target was used as a template to influence the equilibrium. Therefore, only
articles using an adaptive approach are listed, pre-equilibrated DCC examples are omitted.[29–31] The table is adapted from Frei et al. and complemented.[32] [a]
Target Reversible reaction Analysis Library size Equilibration time Method applied for Best affinity Ref.
affinity measurement
Wt Tau RNA Disulfide HPLC-MS and 21 2 days Fluorescence titration EC50 = 70 nM Artigas et al. 2015[33]
NMR
HIV FSS RNA Disulfide MS 12 4 days n.a. n.a. McAnany et al. 2016[34]
Vascular endothelial Imine HRMS 297 24 h In vitro activity against IC50 = 2.4 μM Yang et al. 2016[35]
growth factor receptor cancer cell lines
(VEGFR) 2
Endothiapepsin Acylhydrazone HPLC-MS 90 20 h Inhibition assay IC50 = 54.5 nM Mondal et al. 2016[36]
Ki = 25.4 nM
FimH Acylhydrazone HPLC 8 3 days SPR KD = 273 nM Frei et al. 2017[37]
UDP-galacto-pyranose Acylhydrazone HPLC 11 24 h Fluorescence-based KD = 3 μM MIC = Fu et al. 2017[38]
mutase assay and MIC 26 μg mL–1
Myeloperoxidase (MPO) Hydrazone Activity assay 6 n.a. in vivo activity assay IC50 = 79 nM Soubhye et al. 2017[39]
ecFabH Acylhydrazone 19F-NMR 5 12 h Enzymatic assay IC50 = 3 mM Ektström et al. 2018[40]
Multi-protein strategy on Acylhydrazone DSF and HPLC 10 5 h HPLC-based demethyl- IC50 = 2.6 μM Das et al. 2018[41]
AlkB oxygenases: FTO, ase and DSF assays
ALKBH3 and ALKBH5
Trypanosoma cruzi bromo- Acylhydrazone HPLC-MS 30 n.a. DSF IC50 = 13–23 μM García et al. 2018[42]
domain-containing
(TcBDF3)
G-Quadruplex DNA Imine formation HPLC and ESI-MS 10 24 h n.a. n.a. Jana et al. 2019[43]
[a] DSF = differential scanning fluorimetry, HPLC = high-pressure liquid chromatography, IC50 = half maximal inhibitory concentration, ITC = isothermal titration
calorimetry, KD = dissociation constant, Ki = inhibition constant, MIC = minimum inhibitory concentration, MS = mass spectrometry, n.a. = not available,
NMR = nuclear magnetic resonance, SPR = surface plasmon resonance.
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They were able to reach equilibrium reasonably fast at a com-
paratively high pH of 6.2 by using aniline, as a nucleophilic
catalyst.[12] Previously Dawson and co-workers have shown that
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aniline could serve as a catalyst for acylhydrazone formation
and oxime ligation.[25,26] Derivatives of aniline, which bear sub-
stituents at the aryl ring, are even more effective catalysts.[27]
The acylhydrazone linkage is reversible but sufficiently stable
to allow for direct analysis under acidic conditions and stable
against hydrolysis at physiological pH values, allowing for the
“freezing” of the reversible reaction upon increasing the pH.[24]
An overview of studies published over the past five years in
the field of ptDCC is given in Table 1. It must be noted that
much more work has been published applying DCC for the for-
mation of diverse libraries in the drug-discovery process. For
example the coupling of DCC to DNA-encoded libraries, creat-
ing so called DNA-encoded dynamic combinatorial chemical li-
braries (EDCCLs). Iminobiotin and homotetrameric streptavidin
were used as a model system to identify a bidentate protein/
ligand interaction. The addition of an external stimulus, for ex-
ample a target protein, can shift the thermodynamic equilib-
rium and hence a DNA amplification can be observed after se-
quencing.[28]
2. A Closer Look on the Templating Protein
To obtain meaningful results from DCC experiments, the quality
of the input template is critical. As the equilibrium of the library
shifts by the templating effect of the added protein sample, it
should consist of the target protein as close to its native state
as possible. The quantity of the used template depends on the
protein target, there are reported successful DCC projects with
0.1 to 1.5 equivalents of protein.[29,44] DCC experiments are also
possible with a mixture of proteins, but a well-defined sample
eases up downstream data analysis and reduces the number of
false positives for the desired target.[41]The condition of the pro-
tein sample depends on various variables. For DCC experiments
the purity, concentration, tertiary and quaternary structure of
the protein, additives and contaminations, as well as the pH-
value are of particular importance. During the experiment,
which can take up to several days, protein degradation and
precipitation could occur. The tests described herein should
give an overview and help to choose suitable experimental con-
ditions to plan new DCC experiments. In the next paragraphs,
we will briefly discuss the influence of those factors and suit-
able analytical methods to monitor them.
2.1. Purity
In the case of a mixed or impure protein sample, there might
be several templated reactions proceeding in parallel. It is im-
possible to differentiate between a small fraction of the sample
showing a strong template effect and a large fraction of the
protein pool showing only a weak amplification of a binder.
This will result in overlapping data, which are difficult to ana-
lyze, and may result in false positives. We therefore recommend
starting with the highest protein purity available.
2.2. Stability
Not only the initial state, but also the stability of the templating
protein during the reaction should be checked by preliminary
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tests before conducting a DCC experiment. The time span over
which a DCC experiment, pre-equilibrated or adaptive, is moni-
tored can vary. It depends on the reaction rate and concentra-
tion and should ideally be monitored until the library reaches
an equilibrium state. Usually, the DCL reaches a new equilib-
rium within the first few days, depending on the reversible reac-
tion and conditions used (Table 1). However, if the protein is
stable for longer periods of time, longer equilibration times are
possible, for example up to 20 days for the very stable protease
endothiapepsin (see Section 2.4).[24]
It is important that the protein is not precipitating or degrad-
ing during the experiment. Precipitation of the protein will re-
move the template from the solution. Denaturation of the tem-
plate will lead to entirely new templates, which would affect
the equilibrium state of the DCL. This can lead to random and
irreproducible amplification of compounds by the unordered
protein and a decrease of initially already amplified best binders
of the native template. If the protein target is labile, it is there-
fore necessary to follow the reaction over time to identify the
temporary, templated equilibrium of the DCC library. In this,
compounds amplified by the native state of the template can
be found.
Eventually, after prolonged incubation times, nearly every
protein will degrade and, by this, change the equilibrium of
the DCL again. Compounds amplified in this step should be
disregarded, as they were not templated by the native protein.
Observation of the DCC experiment for longer timeframes than
the template's stability under the specific conditions should
therefore be avoided.
2.3. Buffer and pH
When choosing a buffer for DCC experiments, several different
requirements have to be met. Attention should be paid to pos-
sible side reactions with the DCL or chelation effects. For exam-
ple, Tris buffer could form imines with aldehyde building blocks,
which might influence the formation of the DCL. Some stabili-
zation of the protein is beneficial, but strong interactions of the
buffer with the target protein should also be avoided, for in-
stance, a phosphate buffer for a phosphate binding protein.
The phosphate could compete with possible binders; possible
effects of competition are discussed in more detail in Section
2.5. So far, in most cases common buffer systems have been
used, which are shown in Table 2 and Scheme 2. The choice of
buffer is, however, not limited to the established systems.
Table 2. Buffers commonly used in different DCC reactions. *Tris buffer re-
quires special attention.
Reaction Buffer described in literature
Acylhydrazone formation [6,24,37] Ammonium- and Sodium acetate,
Phosphate, Tris*
Hydrazone formation [45,46] Phosphate, Tris*
Disulfide [47,48] Phosphate, Borate
Thioether [49] Water/DMSO
Imine [13] Water
Boronate ester [50,51] Ammonium acetate, Water
For many protein targets, the stability at room temperature
and the optimal buffer conditions are not known. We therefore
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Scheme 2. Example of possible buffers and the pH ranges of reactions used in DCC experiments.
recommend determining these conditions prior to performing
DCC experiments. As several interdependent factors, like pH,
buffer, ionic strength and ions influence the stability of a pro-
tein, it is difficult to suggest a stepwise flow scheme for the
determination of the ideal buffer composition for a given pro-
tein.[28] Not only the protein but also the exchange chemistry
might be affected significantly by varying these parameters. We
propose to first measure the effect of pH, buffer and ionic
strength over a wide range in parallel. Afterwards, a small selec-
tion (2 to 5) of the most stabilizing combinations can be evalu-
ated for their long-term effect on the protein. Subsequently, the
best condition will then be used to determine the influence of
DMSO (Section 2.6) and, if of interest, additives (Section 2.5).
The selection of the initial buffers could be broadened, in case
no suitable condition was found.
Two or more buffers should be screened per pH value to
distinguish the influence of the buffer component and the pH
value on the stability of the protein. It is also possible to use a
so-called “superbuffer”,[52] a mix of three or more buffer compo-
nents, enabling the adjustment of a wide pH range, without
changing the buffer composition or concentration.
The effect of the buffer components on a protein can be
measured in a straightforward way, by determining the melting
point of the target protein via a thermal-shift assay/differential
scanning fluorimetry (TSA/DSF).[28] In this method, the protein
is incubated together with a lipophilic dye, for example sypro
orange. The dye shows an increase in fluorescence after binding
to the hydrophobic parts of a protein. These are often located
at the inside of a protein and become exposed during tempera-
ture-induced unfolding/melting. The temperature–dependent
increase in fluorescence can be measured in a RT-PCR apparatus
and yields the Tm of the protein.
Other methods, like DSC, ITC and CD (differential scanning
calorimetry, isothermal titration calorimetry and circular dichro-
ism spectroscopy) and the determination of melting points by
CD could also be used to gain information on the interaction
and possible stabilization of the protein with its buffer, but re-
quire a high amount of protein and/or long measurement time.
The TSA, however, offers high throughput and a short assay
time, together with already several published or commercially
available kits in 96-well format.[53,54] These kits were originally
intended to screen for optimal crystallization conditions and
cover several stability-influencing conditions. When performing
DCC experiments, the design of an individual 96-well plate lay-
out, tailored to the buffers and conditions compatible with the
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planned DCC reaction, might be useful. This is a short time
investment, which might pay off quickly in the future, if ptDCC
is used on several different targets.
After a DCC–compatible, stabilizing buffer condition has
been identified, the protein should be checked for its long-
term stability. To check for cleavage of the protein backbone
an analysis by SDS-PAGE is of sufficient sensitivity (Figure 3). To
determine if the protein folding is affected, TSA is again the
method of choice, since the signal directly depends on the un-
folding process of the protein. With prolonged degradation, the
melting point decreases slightly. As a secondary effect of the
degradation, the fluorescence curve can show bi- and multi-
phasic melting points and an overall decrease in signal intensity
and resolution. A fully denatured enzyme will just show a de-
creasing fluorescence signal with no peak from protein unfold-
Figure 3. 12 % SDS-PAGE of different homologues of the enzyme 5-deoxyxyl-
ulose 5-phosphate synthase (DXS) after incubation at RT. The protein on the
upper gel shows no sign of degradation. The second protein, shown on the
lower gel, shows signs of degradation, starting already at day one with a very
faint band around 50 kDa. From day 6 on a decrease of the main protein
band also becomes clear. In the top left corner, a gel-label was removed
using image processing software.
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ing. As controls, a fresh and a heat-treated sample of the target
protein should be included in the experiment.
The tendency of a protein to precipitate is concentration-
dependent. Because of this, the assays determining the protein
stability should be performed with the same protein concentra-
tion that is intended to be used in the DCC experiment. If this
is not possible, due to limited protein availability, the first ex-
periments might be done with less protein. However, at least
for the chosen final condition, the stability assessment should
be repeated with the protein concentration that will be used in
the DCC experiments.
2.4. Functional Enzyme Assay
For enzymatic protein targets, a functional assay can be used
instead of TSA and PAGE measurements for the assessment of
long-term stability. The analysis of activity data of a functional
assay to determine the best experimental conditions of the DCC
experiments leaves less room for interpretation than the analy-
sis of the results of a melting-point analysis. Therefore, if a func-
tional assay is available, and the enzyme is showing catalytic
activity in the desired pH range of the DCC reaction, the activity
assay should be the method of choice.
In a previous study from 2014, we could monitor the activity
of the target protein endothiapepsin by performing a fluores-
cence-based assay (Figure 4). The pH optimum of endothia-
pepsin is 4.5, and the enzymatic activity was not affected even
after 20 days incubation at RT and a pH of 4.6. Considering this
high stability, no buffer optimization was needed.[24]
Figure 4. Activity of endothiapepsin, a pepsin-like aspartic protease, in a fluo-
rescence-based assay at different time intervals of incubation at room tem-
perature. Adapted from Mondal et al.[24]
2.5. Additives and Contaminations
During the purification, the protein might be in contact with
different buffers and conditions. Some of the buffer compo-
nents might remain bound to the protein, even after buffer
exchange. These contaminants might influence the experiment.
It is therefore recommended to critically evaluate the composi-
tion of the protein sample. Not only should the protein storage
buffer be evaluated, but also the origin of the sample.
Common substances that could be found in protein samples
are for example imidazole as a leftover from an IMAC (immobi-
lized metal affinity chromatography) purification step. Protein
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samples are often supplemented with reducing agents like 2-
ME, DTT or TCEP (2-Mercaptoethanol, Dithiothreitol or Tris(2-
carboxyethyl)phosphine) in concentrations up to 10 mM to keep
the protein in a reducing environment. If disulfide formation
is the reversible reaction of choice, the final reducing agent
concentration should be evaluated to make sure that the for-
mation of disulfide bonds is not inhibited.
The effect of additives and contaminations is related to the
volume of the protein sample used in the individual DCC exper-
iments. This not only determines the final concentration of pro-
tein, but also the concentrations of the contaminants. If the
batch-to-batch concentration of the protein varies and its vol-
ume is adjusted to reach the same final concentration in the
DCC experiment, it should be noted that the concentrations
and effects of the additives in the DCC experiment might vary.
Compounds that remain in the protein sample can have an
influence on the DCC reaction or on the target protein. One
should critically check every buffer component on possible in-
terference with the planned exchange chemistry. Performing a
control experiment with all buffer components, in the absence
of protein, can assure that no side reactions are taking place. If
the exact composition of the protein sample is unknown, a
small volume of the buffer might be obtained by concentration
of the protein using an ultrafiltration device and using the flow-
through for the control experiment.
Some agents used during protein purification, such as cryo-
protectants like glycerol or detergents like Tween, will interact
in a non-specific way with the protein surface. From our experi-
ence, if there is no hint that they might affect the experiment,
leftover cryoprotectants and detergents can be tolerated. Spe-
cial care should be taken if cofactors, coenzymes or ions are
supplemented during the purification process to stabilize the
enzyme. The same holds true for buffer components structur-
ally related to those supplements. Everything that binds to the
targeted binding pocket is competing with the DCC library. If a
natural, tight binding cofactor is present during the experiment,
it could prevent the building blocks from binding and therefore
also inhibit their amplification. However, the use of tight bind-
ers can be beneficial in control experiments. If a compound
with a known binding site is inhibiting the formation of some
previously observed binders this can be taken as a hint that the
templated binders are targeting the same protein pocket.
2.6. DMSO
Addition of a small percentage of DMSO to the reaction solu-
tion is a common practice in the design of enzymatic assays to
improve the solubility of hydrophobic compounds. For bio-
chemical assays, DMSO concentrations up to 10 % are regularly
used.[55]
In DCC experiments, the building blocks of the library are
typically dissolved in DMSO stock solutions to enable the easy
assembly of a library. Depending on the library composition
and number of compounds used, the final DMSO concentration
would vary. To keep the reaction conditions comparable, we
recommend adding DMSO up to a concentration that can be
kept constant for all experiments of a project. This fixed concen-
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tration should be evaluated and chosen beforehand, to ensure
the protein tolerates it.
DMSO has a very broad range of effects on proteins, it can
even decrease the solubility and induce precipitation.[56] Both,
rate acceleration, as well as inhibition of the enzyme-catalyzed
reaction by DMSO have been observed. An influence of already
low percentages of DMSO on the enzymatic activity often hints
to DMSO acting as an unspecific effector, interacting with the
active site of the enzyme.[57] If the enzymatic activity is reduced
by DMSO at higher concentrations (>10 % DMSO ), it is often
by influencing the overall protein conformation by displacing
water molecules bound to the surface and unfolding the pro-
tein.[58] On the other hand, there are DMSO-tolerant enzymes
known which show activity up to 80 % DMSO.[57] Enzyme activ-
ity assays are the method of choice to estimate the effect of
DMSO on an enzyme. If no activity assay is available, the effect
of DMSO could also be measured using TSA, however, interac-
tions with the active site are difficult to detect with this
method. We often observe a small effect on the Tm of a protein,
but a strong effect on the enzymatic activity. Taken together,
the DMSO concentration has several effects on the protein
structure. The benefits of DMSO addition need to be weighed
against the risk of creating an artificial enzymatic fold, which
could amplify compounds that would not bind under native
conditions. Therefore, the DMSO concentration should be as
low as possible, in our lab up to 5 % are regularly used.
2.7. Temperature
To speed up the rate at which the DCL reaches equilibrium, the
experiments are normally performed at room temperature. For
labile proteins, a lower reaction temperature may be necessary,
which can improve the stability of the proteins. At the same
time, the equilibration rate is decreased, leading to a prolonged
incubation time. The optimal temperature for protein stability
in DCC could vary from enzyme to enzyme and thus needs to
be evaluated in each individual case but room temperature is
used in most cases.
3. Setting up a ptDCC Experiment
When crystal structures are available, or even co-crystal struc-
tures, a structure-based approach can be undertaken to design
promising building blocks. In this case, also non-binders could
be designed as control elements, which are not supposed to
Table 3. General protocol for DCC and protocol for DCC coupled to 1H-STD-NMR. * Aniline or another nucleophilic catalyst could be added when required.
** In a control experiment, no protein is added. *** Buffer conditions to guarantee protein stability should be determined a priori.
Final concentration in general DCC Final concentration used in DCC coupled to 1H-STD-NMR[24]
Aldehyde 0.1 mM 0.4 mM
Hydrazide 0.1–0.3 mM 1 mM (for each of the five hydrazides)
DMSO 5–10 % 5–10 %
Aniline* 10 mM –
Protein** 10–100 μM 4 μM
Buffer*** 0.1 M Ammonium acetate in D2O (0.1 M, pH 4.6)
pH* Acidic–neutral pH 4.6
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emerge as hits. The type of reversible linkage should be care-
fully selected because it influences the molecular recognition
by the target. For example, the acylhydrazone linkage resem-
bles the amide functionality and features hydrogen-bond do-
nors and acceptors. We showed that by combining DCC with
de novo structure-based design, the risks associated with this
attractive approach are reduced.[24]
3.1. Formation of the DCLs
The building blocks might have to be dissolved in DMSO, allow-
ing them as well as the formed products to stay soluble in the
final mixture. In principle, they could also be dissolved in the
desired buffer, which would be most ideal. In 2014, we coupled
DCC to saturation-transfer difference (STD) NMR spectroscopy,
which requires lower concentrations of protein than a general
DCC experiment (Table 3). STD-NMR spectroscopy enables se-
lection of the binders from the DCL, since the intensity of these
signals is stronger due to a more efficient saturation transfer.
As a result, STD-NMR spectra cannot be used to determine con-
centrations of DCL members and therefore amplification cannot
be calculated. In follow-up experiments, it is possible to deter-
mine the KD value of a ligand via STD-NMR or other biophysical
assays.[59]
The ratio of hydrazides vs. aldehydes should allow for the
formation of all possible products, therefore at least one equiva-
lent of each hydrazide per aldehyde should be used. For exam-
ple, if three aldehydes are used then at least three equivalents
of each hydrazide should be added, making sure that there is
an excess of hydrazides. When required, a nucleophilic catalyst
like aniline could be added. The most frequently used concen-
tration of DMSO lies around 5–10 %.
Control experiments should be considered, which should
clarify where binding of molecules to the protein occurs and if
it is specific or unspecific. This could for example be performed
by the addition of a known inhibitor. If the previously observed
amplification is not observedany longer, then the hit com-
pounds are competitive binders. Based on the work of Danieli
et al., B. Ernst and co-workers propose that the use of bovine
serum albumin (BSA), as a negative control template for which
no amplification is expected since the binding pocket is differ-
ent, is not a good control since it could influence the library
composition, whilst the use of a competitive inhibitor is better.
BSA has been used in DCC to show that the applied library only
gives hits with the real target and that BSA would yield the
same result as the blank.[32,60] BSA is commonly known for its
Minireview
stability and was thought not to interfere with biological reac-
tions, however recently DCC experiments have even been used
to target BSA.[61]
3.2. Analysis of the DCLs
Different techniques such as fluorescence-polarization, SPR, ITC,
MST, STD-NMR, crystallography and others can be used to eval-
uate and possibly optimize obtained hits. We and Rademann
and co-workers have reviewed the analytical methods used in
protein-templated dynamic combinatorial chemistry to detect
hit compounds.[23,62]
A commonly applied method to analyze DCC experiments is
the recording of HPLC-MS chromatograms of the libraries. As
an illustrative example of the comparative approach, we drew
HPLC chromatograms of a blank library and a target library (Fig-
ure 5). When we compare both chromatograms, we see that
peak number five has increased in the library containing the
target, whereas peaks three and six have decreased. The total
amount of building blocks stays the same, only the equilibrium
can be shifted towards one or more products.
Figure 5. Schematic example of HPLC chromatograms: (a) blank library
chromatogram, (b) target library chromatogram.
In order to accurately determine the amplification or de-
crease of peaks, their relative peak areas (RPA) should be com-
pared. The fictional RPAs of both chromatograms in Figure 5
are given in Table 4. The amplification factor in percentage can
Table 4. Example of relative peak areas (RPA) obtained from HPLC chromatograms from Figure 4.
Peak number Relative peak area in blank [%] Relative peak area in target [%] Amplification in % Amplification in “fold”
1 10 10 – 1
2 15 15 – 1
3 20 16 –20 % 0.8
4 16 16 – 1
5 12 24 100 % 2
6 27 19 –30 % 0.7
Total 100 % 100 %
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be calculated by Equation (1), where the amplification factor in
“fold” is given by Equation (2). Using these two equations, the
product at peak five has increased by 100 % or twofold. Frei et
al. report on a particularly thorough analysis of a DCL using the




3.3. DCL Analyzed with STD-NMR spectroscopy
Inspired by the work of Ramström and co-workers,[20] we ana-
lyzed the formed DCLs by STD-NMR spectroscopy (Scheme 3).
Five sub-libraries enabled a clear analysis. As a control with
a known binder we used saquinavir (Ki = 48 nM), a potent
peptidic inhibitor, to differentiate specific from nonspecific
binding. Each sub-library contained all five hydrazides and one
of the aldehyde building blocks and was allowed to equilibrate
for 24 hours before adding the target. By analyzing the imine-
type proton signals of the acylhydrazone products in the 1H-
STD-NMR spectra (Figure 6), we identified in total eight binders.
To confirm the results from STD-NMR, we performed an en-
zyme-inhibition assay and showed that the hits were inhibitors
with IC50 values ranging from 12.8 μM to 365 μM. The high hit
rate in this report may be a result of the powerful and synergis-
tic combination of de novo structure-based drug design and
DCC. In addition, it is due to use of five sublibraries in which
the best binder of each library is detected, whereas in a regular
ptDCC setup only the overall best binders will be discovered. In
STD-NMR the protein is used as a tool to analyze the library,
whereas in a ptDCC experiment the protein influences the equi-
librium and hence the concentrations
4.4. How to proceed after obtaining hits
Having obtained a validated hit, identified by de novo struc-
ture-based drug design in combination with DCC and STD-
NMR, we have used a structure-based design approach to im-
prove the molecular recognition by the target.[63] In this specific
case, we were fortunate to have an X-ray crystal structure of
the target endothiapepsin in complex with the hit. If this is
not the case, optimization is still possible, relying on structure–
activity relationships.
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Scheme 3 . Formation of dynamic combinatorial library and enzymatic selection of the best binders by 1H-STD-NMR analysis. Adapted from Mondal et al.[24]
Figure 6. DCL generated from H1–5 + A4: (aromatic region) a) 1H-STD-NMR
spectrum of H1–5 + A4, b) 1H-NMR spectrum of H1–5 + A4, c) 1H-NMR
spectrum of H3+A4, d) 1H-NMR spectrum of H4+A4 (2 singlets correspond
to the E/Z isomers), e) H1+A4, f ) H2+H4 and g) H5+A4. Adapted from Mon-
dal et al.[24]
Conclusions
There are a number of steps, which should be carefully taken
into account, in order to obtain active hits by DCC. If informa-
tion on the target is available, e.g. a crystal-structure, one could
consider a structure-based design when choosing the building
blocks. The type of reversible linkage to be used can be chosen
at this stage. Conditions necessary for the equilibration to take
place should be compatible with the target. After establishing
conditions, which will ensure the target remains folded, the ac-
tual DCC experiment can be started. To do so, stock solutions
of building blocks, catalyst and protein should be prepared. The
formed DCLs can be analyzed by different techniques such as
STD-NMR or HPLC-MS. Compounds that have been selected by
the target, and their biochemical properties should be evalu-
ated and possibly optimized in further studies.
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